POPULARITY
21 episodes with gefitinib
26 episodes with gefitinib
4 episodes with gefitinib
Dr. Nasser Hanna, Indiana University Health, reviews efforts to utilize targeted therapies as consolidation after chemoradiation in locally advanced NSCLC.
Dr. Nasser Hanna, Indiana University Health, reviews efforts to utilize targeted therapies as consolidation after chemoradiation in locally advanced NSCLC.
Dr. Nasser Hanna, Indiana University Health, reviews efforts to utilize targeted therapies as consolidation after chemoradiation in locally advanced NSCLC.
Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.
Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.
Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.
MSKCC medical oncologist Dr. Greg Riely reviews the optimal first line treatment of patients with an EGFR mutation-positive advanced lung cancer.
MSKCC medical oncologist Dr. Greg Riely reviews the optimal first line treatment of patients with an EGFR mutation-positive advanced lung cancer.
MSKCC medical oncologist Dr. Greg Riely reviews the optimal first line treatment of patients with an EGFR mutation-positive advanced lung cancer.
Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.
Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.
Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.
Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.
Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.
Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.
Dr. Greg Riely, medical oncologist from MSKCC, considers the evidence on whether there are clinically significant differences among the currently available first and second generation oral EGFR inhibitors for patients with an EGFR mutation.
Dr. Greg Riely, medical oncologist from MSKCC, considers the evidence on whether there are clinically significant differences among the currently available first and second generation oral EGFR inhibitors for patients with an EGFR mutation.
Dr. Greg Riely, medical oncologist from MSKCC, considers the evidence on whether there are clinically significant differences among the currently available first and second generation oral EGFR inhibitors for patients with an EGFR mutation.
Medical oncologist Dr. Greg Riely, MSKCC, discusses evidence for whether there are clinically significant differences among specific EGFR mutations that should lead to differences in management.
Medical oncologist Dr. Greg Riely, MSKCC, discusses evidence for whether there are clinically significant differences among specific EGFR mutations that should lead to differences in management.
Medical oncologist Dr. Greg Riely, MSKCC, discusses evidence for whether there are clinically significant differences among specific EGFR mutations that should lead to differences in management.
Dr. Jack West, medical oncologist, reviews evidence in favor of adding Avastin (bevacizumab) to the EGFR inhibitor Tarceva (erlotinib) for patients with lung cancer that harbors an activating EGFR mutation.
Dr. Jack West, medical oncologist, reviews evidence in favor of adding Avastin (bevacizumab) to the EGFR inhibitor Tarceva (erlotinib) for patients with lung cancer that harbors an activating EGFR mutation.
Dr. Jack West, medical oncologist, reviews evidence in favor of adding Avastin (bevacizumab) to the EGFR inhibitor Tarceva (erlotinib) for patients with lung cancer that harbors an activating EGFR mutation.
Acquired Resistance Forum Video #15: Dr. Pasi Jänne of Dana-Farber Cancer Institute spoke about EGFR inhibitors available to patients when Tarceva stops working for them.
Acquired Resistance Forum Video #15: Dr. Pasi Jänne of Dana-Farber Cancer Institute spoke about EGFR inhibitors available to patients when Tarceva stops working for them.
Acquired Resistance Forum Video #15: Dr. Pasi Jänne of Dana-Farber Cancer Institute spoke about EGFR inhibitors available to patients when Tarceva stops working for them.
Will the success seen for stage IV patients receiving targeted therapies translate into cure for stage III patients? Dr. Daniel Morgensztern of the Washington University School of Medicine talks about what research is ongoing to answer that question.
Will the success seen for stage IV patients receiving targeted therapies translate into cure for stage III patients? Dr. Daniel Morgensztern of the Washington University School of Medicine talks about what research is ongoing to answer that question.
Will the success seen for stage IV patients receiving targeted therapies translate into cure for stage III patients? Dr. Daniel Morgensztern of the Washington University School of Medicine talks about what research is ongoing to answer that question.
Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes what research indicates may be more successful treatments for EGFR lung cancer patients.
Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes what research indicates may be more successful treatments for EGFR lung cancer patients.
Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes what research indicates may be more successful treatments for EGFR lung cancer patients.
Dr. Phil Bonomi, from Rush University, describes the generations of EGFR inhibitors beginning with Gefitinib (Iressa).
Dr. Phil Bonomi, from Rush University, describes the generations of EGFR inhibitors beginning with Gefitinib (Iressa).
Dr. Phil Bonomi, from Rush University, describes the generations of EGFR inhibitors beginning with Gefitinib (Iressa).
Drs. Jack West, Mary Pinder, and Nate Pennell discuss options for managing acquired resistance to EGFR TKIs and ALK inhibitors in patients with advanced NSCLC and a driver mutation.
Drs. Jack West, Mary Pinder, and Nate Pennell discuss options for managing acquired resistance to EGFR TKIs and ALK inhibitors in patients with advanced NSCLC and a driver mutation.
Drs. Jack West, Mary Pinder, and Nate Pennell discuss options for managing acquired resistance to EGFR TKIs and ALK inhibitors in patients with advanced NSCLC and a driver mutation.
Dr. David Spigel, Sarah Cannon Cancer Center, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.
Dr. David Spigel, Sarah Cannon Cancer Center, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.
Dr. David Spigel, Sarah Cannon Cancer Center, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.
Dr. Sarah Goldberg, from Yale Cancer Center, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified during first line chemotherapy. When should we switch treatments?
Dr. Sarah Goldberg, from Yale Cancer Center, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified during first line chemotherapy. When should we switch treatments?
Dr. Sarah Goldberg, from Yale Cancer Center, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified during first line chemotherapy. When should we switch treatments?
Dr. Phil Bonomi, from Rush University, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.
Dr. Phil Bonomi, from Rush University, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.
Dr. Phil Bonomi, from Rush University, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.
Dr. Rosalyn Juergens, McMaster University, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?
Dr. Rosalyn Juergens, McMaster University, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?
Dr. Rosalyn Juergens, McMaster University, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?
Dr. Ravi Salgia from University of Chicago discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.Â
Dr. Ravi Salgia from University of Chicago discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.Â
Dr. Ravi Salgia from University of Chicago discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.Â
Dr. Oxnard from Dana Farber Cancer Institute provides his insight on which patients with advanced non-small cell lung cancer he pursues molecular testing for, and which molecular markers are the highest priority.
Dr. Greg Riely offers his view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?
Dr. Oxnard from Dana Farber Cancer Institute provides his insight on which patients with advanced non-small cell lung cancer he pursues molecular testing for, and which molecular markers are the highest priority.
Dr. Greg Riely offers his view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?
Dr. Greg Riely offers his view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?
Dr. Oxnard from Dana Farber Cancer Institute provides his insight on which patients with advanced non-small cell lung cancer he pursues molecular testing for, and which molecular markers are the highest priority.
Dr. Jack West describes recent information on the probability that someone with a rare EGFR mutation on exon 20, rather than a more common "activating" mutations on exon 19 or 21, will benefit from an oral EGFR inhibitor vs. standard chemotherapy.
Dr. Jared Weiss, Medical Oncologist at UNC-Chapel Hill, reviews lung cancer highlights in 2011, focusing here on treatments focusing on the EGFR axis.
Dr. Jared Weiss, Medical Oncologist at UNC-Chapel Hill, reviews lung cancer highlights in 2011, focusing here on treatments focusing on the EGFR axis.
This podcast describes the analysis of the IPASS study population by EGFR mutation and EGFR FISH biomarker status, and also discusses the results and controversial analysis of overall survival from this trial.
Dr. Lecia Sequist of Massachusetts General Hospital answers questions about acquired resistance to EGFR tyrosine kinase inhibitors and repeat biopsies of tumors over the course of treatment for advanced NSCLC.
Dr. Lecia Sequist of Massachusetts General Hospital answers questions about acquired resistance to EGFR tyrosine kinase inhibitors and repeat biopsies of tumors over the course of treatment for advanced NSCLC.
Dr. Lecia Sequist of Massachusetts General Hospital describes the results of their experience in repeating biopsies in patients over the course of their ongoing treatment for advanced NSCLC and the changes in tumor characteristics over time.
Dr. Lecia Sequist of Massachusetts General Hospital describes the results of their experience in repeating biopsies in patients over the course of their ongoing treatment for advanced NSCLC and the changes in tumor characteristics over time.
Dr. Lecia Sequist of Massachusetts General Hospital presents a summary of the challenge of acquired resistance to EGFR tyrosine kinase inhibitors like Tarceva (erlotinib) and Iressa (gefitinib), along with emerging ideas for overcoming it.
Dr. Lecia Sequist of Massachusetts General Hospital presents a summary of the challenge of acquired resistance to EGFR tyrosine kinase inhibitors like Tarceva (erlotinib) and Iressa (gefitinib), along with emerging ideas for overcoming it.
© 2020-2025 Ivy Podcast Discovery LLC
